相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions
Jason H. Karnes et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59 (2019)
Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population
Kavish Ihtisham et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2019)
A Screening Test for HLA-B*15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events
Hua Fang et al.
FRONTIERS IN PHARMACOLOGY (2019)
Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model
Rob ter Heine et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update
Elizabeth J. Phillips et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database
Andrea Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions
Kittika Yampayon et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants
Jason H. Karnes et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach
Rachel G. Greenberg et al.
CLINICAL NEUROPHARMACOLOGY (2016)
Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population
Wichittra Tassaneeyakul et al.
PHARMACOGENETICS AND GENOMICS (2016)
Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes
Carolina Cespedes-Garro et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
CYP2C9 Genotype vs. Metabolic Phenotype for Individual Drug Dosing-A Correlation Analysis Using Flurbiprofen as Probe Drug
Silvia Vogl et al.
PLOS ONE (2015)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing
K. E. Caudle et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Genetic Variants Associated With Phenytoin-Related Severe Cutaneous Adverse Reactions
Wen-Hung Chung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing
M. S. Hershfield et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy
Carlos A. Twardowschy et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2013)
HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review
V. L. Yip et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
M. A. Martin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
PharmGKB summary: phenytoin pathway
Caroline F. Thorn et al.
PHARMACOGENETICS AND GENOMICS (2012)
Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients
Chin-Chuan Hung et al.
PHARMACOGENOMICS (2012)
ALDEN, an Algorithm for Assessment of Drug Causality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case-Control Analysis
B. Sassolas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Effects of Antiepileptic Drugs on Lipids, Homocysteine, and C-Reactive Protein
Scott Mintzer et al.
ANNALS OF NEUROLOGY (2009)
Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
Jonatan D. Lindh et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data
Makiko Kusama et al.
PHARMACEUTICAL RESEARCH (2009)
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
Christine Lonjou et al.
PHARMACOGENETICS AND GENOMICS (2008)
Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms
CC Hung et al.
THERAPEUTIC DRUG MONITORING (2004)
Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data
CR Lee et al.
PHARMACOGENETICS (2002)
The effect of genetic polymorphism of cytochrome P450CYP2C9 on phenytoin dose requirement
J van der Weide et al.
PHARMACOGENETICS (2001)
分享论文
